new directors review . ann

22nd July 2004
SCIENTIFIC REVIEW OF SOLBEC’S SBP002
BY PROFESSOR JOHN PAPADIMITRIOU AM, OSJ, MD, PhD,
FRCPath, FRACPA, FIBiol
Summary
• Professor Papadimitriou has carried out a complete review of Solbec’s scientific, nonclinical
and pre-clinical data
• Professor Papadimitriou informed the board that he was impressed with the quality of
research, the volume of data on SBP002 and the scientific direction that management
has adopted.
As a part of Solbec’s commitment to scientific excellence and our commitment to transparency to the
market the recent appointment of Professor Papadimitriou to the board of Solbec has provided the
opportunity for a complete review of the company’s science, non-clinical and pre-clinical data.
Professor Papadimitriou’s review confirms that:
• Solbec has a detailed understanding of the chemistry of SBP002.
• The non-clinical, pre-clinical, and proof of concept using in vitro, in vivo and ex vivo data
confirm the anti cancer activity of the drug.
• The mode of action appears to be unique and is different from current therapies. This increases
the potential for different applications and there is good argument that SBP002 can be used in
combination with other existing therapies to increase the overall anti cancer activity.
Professor Papadimitriou informed the board that he was impressed with the quality of research, the
volume of data on SBP002 and the scientific direction that management has adopted.
In addition he indicated that the base technology could also support a platform of potential uses.
For further information contact
Stephen Carter Professor John Papadimitriou
Managing Director Director
(08) 94467555 (08) 9346 2769
[email protected] [email protected]